In this real-world study of ICI use in the era of adjuvant therapy for melanoma, we found that risk of all-cause AKI increases with more advanced cancer stage, yet the risk of ICI-associated AKI is only driven by the use of anti-CTLA-4/PD-1 combination therapy and not cancer stage. This evidence concerns the gene PDCD1 and acute kidney injury.